<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benign pigmented skin lesions other than melanocytic nevi (moles)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benign pigmented skin lesions other than melanocytic nevi (moles)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Benign pigmented skin lesions other than melanocytic nevi (moles)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie V Schaffer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean L Bolognia, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raegan Hunt, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Benign pigmented skin lesions and melanocytic nevi (moles) are common in children and adolescents. Benign pigmented skin lesions, including lentigines, café-au-lait macules, Becker nevi, and dermal melanocytoses (Mongolian spots, nevus of Ota, and nevus of Ito), will be discussed below. Melanocytic nevi and melanocytic nevi variants are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">"Congenital melanocytic nevi"</a> and  <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">LENTIGO</span><span class="headingEndMark"> — </span>Lentigines are benign pigmented macules that result from increased activity of epidermal melanocytes [<a href="#rid1">1</a>]. In contrast to ephelides (freckles) that are often seen in children with lightly pigmented skin and fade in the absence of sun exposure, lentigines are persistent. There are two major types of lentigines: simple lentigo and solar lentigo. The mucosal melanotic macule is a variant of simple lentigo that is located on mucosal surfaces, in particular the lower lip.</p><p class="headingAnchor" id="H3"><span class="h2">Simple lentigo</span><span class="headingEndMark"> — </span>Simple lentigines often appear during childhood as sharply circumscribed, round-to-oval, uniformly brown or brownish-black macules that are usually &lt;5 mm in diameter. There are typically few lesions, with no predilection for sun-exposed sites. However, multiple lentigines may be seen in a variety of disorders  (<a class="graphic graphic_table graphicRef66428" href="/z/d/graphic/66428.html" rel="external">table 1</a>), and lentigines may increase in number or darken in patients with Addison's disease or other syndromes associated with elevated circulating levels of adrenocorticotropic hormone. (See  <a class="medical medical_review" href="/z/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Mucosal melanotic macule</span><span class="headingEndMark"> — </span>Mucosal melanotic macules, which most commonly develop on the vermilion portion of the lower lip, have a predilection for White adolescent girls and young women [<a href="#rid2">2,3</a>]. Mucosal melanotic macules may also occur on the oral mucosa and genitalia. Patients present with one or more brown to black macules, sometimes with irregular borders and mottled pigmentation. Genital lesions are occasionally &gt;1 cm in diameter.</p><p>Multiple perioral and oral mucosal melanotic macules characterize congenital disorders, such as Peutz-Jeghers and Laugier-Hunziker syndromes. Multiple genital melanotic macules are a feature of Bannayan-Riley-Ruvalcaba syndrome (a type of phosphatase and tensin homolog [PTEN] hamartoma-tumor syndrome)  (<a class="graphic graphic_table graphicRef66428" href="/z/d/graphic/66428.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Genetic syndromes associated with lentiginosis'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Solar lentigo</span><span class="headingEndMark"> — </span>In contrast to simple lentigines, solar lentigines appear only in sun-exposed areas, particularly in sites of greatest cumulative exposure (eg, the face, dorsal hands, extensor forearms, upper trunk) [<a href="#rid4">4</a>]. Because the incidence of solar lentigines increases with age, they are most often seen in adults. However, solar lentigines can develop in children with lightly pigmented skin who have had significant sun exposure, especially on the shoulders following severe sunburns. Multiple tan to dark brown macules, often with irregular borders, are typically present. The lesions range from a few millimeters to &gt;1 cm in diameter  (<a class="graphic graphic_picture graphicRef70005" href="/z/d/graphic/70005.html" rel="external">picture 1</a>).</p><p>Children with xeroderma pigmentosum develop numerous solar lentigines at an unusually early age  (<a class="graphic graphic_table graphicRef66428" href="/z/d/graphic/66428.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/15466.html" rel="external">"Xeroderma pigmentosum"</a>.)</p><p>Large, jagged solar lentigines are a characteristic finding in patients with type 2 oculocutaneous albinism. (See  <a class="medical medical_review" href="/z/d/html/15469.html" rel="external">"Oculocutaneous albinism"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The major consideration in the clinical differential diagnosis of a simple lentigo is a junctional melanocytic nevus. (See  <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)", section on 'Common acquired melanocytic nevi'</a>.)</p><p>The differential diagnosis of a genital melanotic macule that has irregular borders and abnormal pigmentation may include early acral lentiginous melanoma of the genitalia [<a href="#rid5">5</a>]. Dermoscopic findings of ring-like and parallel, brown streak patterns support a diagnosis of benign mucosal melanotic macule [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/93603.html" rel="external">"Dermoscopy of mucosal lesions"</a>.)</p><p>Acral lentiginous melanoma of the genitalia is unusual in children and adolescents. If the diagnosis is unclear and there is no palpable component, a shave biopsy can be performed to make the distinction. (See  <a class="medical medical_review" href="/z/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma", section on 'Acral lentiginous melanoma'</a>.)</p><p>In children, ephelides are the major consideration in the differential diagnosis of solar lentigines, since both are characterized by multiple pigmented macules in sun-exposed areas. However, ephelides fade in the winter, whereas solar lentigines are present year round [<a href="#rid8">8</a>]. Lentigines also tend to be larger than ephelides. In adults, the differential diagnosis is primarily macular seborrheic keratoses and, occasionally, lentigo maligna.</p><p>Some variants of solar lentigines, such as ink-spot lentigines  (<a class="graphic graphic_picture graphicRef112132" href="/z/d/graphic/112132.html" rel="external">picture 2</a>) and tanning bed-induced lentigines, have dark pigmentation and a stellate outline that may mimic early melanoma. (See  <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Management</span><span class="headingEndMark"> — </span>Solar lentigines that are of cosmetic concern can be treated with liquid nitrogen cryotherapy, lasers that target melanin (eg, quality-switched [Q-switched] ruby laser, picosecond potassium titanyl phosphate [KTP] laser, picosecond alexandrite laser), or intense pulsed light (broadband light). (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation", section on 'Lentigines'</a>.)</p><p>Although solar lentigines themselves have no malignant potential, they represent a sign of photodamage that indicates an increased risk for the development of melanoma and nonmelanoma skin cancers during adulthood. In children and adolescents with solar lentigines, a skin examination should be included in the annual physical examination performed by the primary care provider. If the patient also has atypical or numerous nevi, or a family history of melanoma, then referral to a dermatologist is often warranted. (See  <a class="medical medical_review" href="/z/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/5337.html" rel="external">"Cutaneous squamous cell carcinoma: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">"Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">CAFÉ-AU-LAIT MACULE</span><span class="headingEndMark"> — </span>Café-au-lait macules (CALM) are flat pigmented lesions that may be present at birth or appear during early childhood, often first becoming noticeable following sun exposure  (<a class="graphic graphic_picture graphicRef57807 graphicRef73651 graphicRef50599" href="/z/d/graphic/57807.html" rel="external">picture 3A-C</a>). They represent localized areas of increased melanogenesis, the etiology of which is not known except when associated with conditions such as McCune-Albright syndrome (mosaic disorder due to a somatic mutation in the <em>GNAS</em> gene encoding the stimulatory G protein's alpha subunit) or neurofibromatosis type 1 (NF1, results from loss-of-function mutations in the <em>NF1</em> tumor suppressor gene). Although several studies have shown that a single CALM can be found in 25 to 35 percent of children, &lt;1 percent of children have ≥3 CALM [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Genetic syndromes associated with café-au-lait macules'</a>.)</p><p>CALM range from a few millimeters to &gt;15 cm in size, and they enlarge in proportion to the growth of the child. Their color varies from tan to dark brown and is usually uniform, although in some cases, perifollicular hypopigmentation or a few darker macules may be apparent within the lesions. In general, the color of CALM is a few shades darker than that of the uninvolved skin [<a href="#rid10">10</a>]. Interestingly, CALM that occur within a Mongolian spot are often surrounded by a halo of normally pigmented skin [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/119230.html" rel="external">"Skin lesions in the newborn and infant", section on 'Dermal melanocytosis'</a>.)</p><p>In patients with "pigmentary mosaicism" (including the small subset with McCune-Albright syndrome), CALM may have a block-like distribution with midline demarcation and an irregular, jagged outline ("coast of Maine")  (<a class="graphic graphic_picture graphicRef96333" href="/z/d/graphic/96333.html" rel="external">picture 4</a>). Some authors refer to this as "segmental pigmentation disorder." (See  <a class="medical medical_review" href="/z/d/html/97404.html" rel="external">"Pigmentary mosaicism (hypomelanosis of Ito)"</a>.)</p><p>In contrast, CALM in patients with NF1 and related conditions classically have a relatively smooth border ("coast of California")  (<a class="graphic graphic_picture graphicRef50599" href="/z/d/graphic/50599.html" rel="external">picture 3C</a>). Patients with NF1 also tend to have greater numbers of CALM in a more widespread distribution (with the exception of segmental NF1). These CALM have been referred to as "typical" based on their regular borders and uniform pigmentation. Larger CALM in individuals with NF1 should be palpated to exclude the possibility of an underlying plexiform neurofibroma. Histologic features cannot differentiate among CALM in patients with McCune-Albright syndrome, other forms of "pigmentary mosaicism," and NF1. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Hyperpigmented patches over the posterior axis are occasionally associated with underlying spinal dysraphism, especially in the presence of additional cutaneous findings such as focal hypertrichosis or a lipoma.</p><p class="headingAnchor" id="H9"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>In a neonate, the differential diagnosis of a single CALM includes the initial stage of a speckled lentiginous nevus (ie, before the appearance of superimposed "spots") or a relatively flat congenital melanocytic nevus (which will likely become more elevated over time). Additional diagnostic considerations may include mastocytoma, postinflammatory hyperpigmentation, and phytophotodermatitis.</p><p>A Becker nevus should be considered for large, solitary lesions that break up into smaller macules at their periphery (with or without associated hypertrichosis), particularly when located on the upper lateral trunk or when onset occurs around the time of puberty. (See <a class="local">'Becker nevus'</a> below.)</p><p>The key question in the evaluation of a child with multiple CALM is whether these lesions represent a cutaneous marker of an underlying systemic disorder. In a longitudinal study of 41 children with ≥6 CALM, 24 (60 percent) were found to have NF1, 6 had segmental NF1, and 3 were diagnosed with other syndromes  (<a class="graphic graphic_table graphicRef66428" href="/z/d/graphic/66428.html" rel="external">table 1</a>); only eight (20 percent) had no manifestations of an associated condition [<a href="#rid12">12</a>]. In another retrospective study of 110 children (median age three years) who presented with CALM but no other features of NF1, 34 of 44 (77 percent) of those with ≥6 "typical" CALM (distinct regular borders, uniform pigmentation) eventually met criteria for NF1 (almost all before age six years). In contrast, 2 of 15 (15 percent) of those with ≥6 "atypical" CALM (irregular borders, nonhomogeneous pigmentation) and 0 of 51 of those with &lt;6 CALM eventually met criteria for NF1 [<a href="#rid13">13</a>].</p><p>The presence of ≥6 CALM (measuring ≥1.5 cm in adults and ≥0.5 cm in prepubertal children) is a criterion for the diagnosis of NF1 that is met by 90 percent of patients by early adulthood. Segmental NF1 (due to mosaicism for a mutation in the <em>NF1</em> gene) can present with various combinations of multiple CALM, "freckling" (multiple small lentigines), or neurofibromas; the pigmentary abnormalities may have a block-like distribution pattern or follow the lines of Blaschko. In contrast to NF1, multiple CALM are found in a minority of patients with <em>NF2</em>-related schwannomatosis (NF2; bilateral vestibular schwannomas), making their presence less useful in establishing the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)"</a>.)</p><p>Legius syndrome, which is secondary to a loss-of-function germline mutation in the <em>SPRED1</em> gene, has a cutaneous phenotype that partially overlaps with that of NF1 (CALM, freckling) but lacks neurofibromas or Lisch nodules [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Neurofibromatosis type 1-like syndrome (Legius syndrome)'</a>.)</p><p>Familial CALM, unassociated with other abnormalities, may also occur outside the setting of Legius syndrome [<a href="#rid15">15-17</a>]. Pigmentary disorders that can present with multiple CALM include piebaldism (CALM in leukodermic and uninvolved skin) and familial progressive hyper- and hypopigmentation. Other conditions associated with multiple CALM include Noonan syndrome, Noonan syndrome with multiple lentigines (previously known as LEOPARD [<strong>l</strong>entigines, <strong>e</strong>lectrocardiogram abnormalities, <strong>o</strong>cular hypertelorism, <strong>p</strong>ulmonic stenosis, <strong>a</strong>bnormal genitalia, <strong>r</strong>etardation of growth, and sensorineural <strong>d</strong>eafness] syndrome), constitutional mismatch repair-deficiency (CMMR-D) syndrome (childhood tumor syndrome with NF1 phenotype), ataxia-telangiectasia, phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome, Russell-Silver syndrome, and Bloom syndrome. (See  <a class="medical medical_review" href="/z/d/html/5832.html" rel="external">"Causes of short stature", section on 'Noonan syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Constitutional mismatch repair-deficiency syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a> and  <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/5832.html" rel="external">"Causes of short stature", section on 'Silver-Russell syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">"Bloom syndrome"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Management</span><span class="headingEndMark"> — </span>If desired for cosmetic reasons, CALM can be treated with pigment-specific lasers, such as the quality-switched (Q-switched) ruby, Q-switched alexandrite, and Q-switched neodymium:yttrium aluminum garnet (Nd:YAG) lasers; nonablative fractional 1550 nm erbium-doped fiber laser; and alexandrite picosecond laser. However, multiple treatment sessions are usually required, responses are variable, recurrences are common, and there is a risk of side effects, such as persistent hyperpigmentation or hypopigmentation. (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation", section on 'Cafe-au-lait macules'</a>.)</p><p>Infants and young children with ≥6 CALM should be evaluated for other manifestations of NF1 (eg, plexiform neurofibromas, sphenoid or tibial dysplasia, and Lisch nodules) and followed with annual physical examinations that include measurement of blood pressure and examination of the skin and eyes during the first decade of life [<a href="#rid18">18,19</a>]. Referral to a pediatric dermatologist or specialized NF1 clinic can also be considered. Of note, comprehensive testing of the <em>NF1</em> gene is clinically available and can identify the underlying mutation in ≥95 percent of nonfounder patients who meet the diagnostic criteria for NF1, allowing an accurate diagnosis to be made in young children who do not (yet) meet these criteria. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">BECKER NEVUS</span><span class="headingEndMark"> — </span>Becker nevus, also called Becker melanosis, is a fairly common benign cutaneous hamartoma with epidermal or dermal elements [<a href="#rid18">18</a>]. Becker nevi can be present at birth, but the majority are first noticed around puberty. This timing of onset, along with the male-to-female ratio of 5:1, the increase in the number of terminal hairs seen within many lesions, and reports of acne vulgaris localized to Becker nevi, has raised the possibility of androgenic stimulation as an underlying factor in their pathogenesis [<a href="#rid20">20</a>]. Evidence suggests that somatic mutations of beta-actin (<em>ACTB</em>) in pilar muscles are associated with Becker nevus [<a href="#rid21">21</a>].</p><p>A Becker nevus classically manifests unilaterally on the shoulder and upper trunk as a tan to brown patch or thin plaque. Less often, lesions occur on the lower trunk, thigh, or in other sites. The margins are usually irregular and break up into "islands" at the periphery  (<a class="graphic graphic_picture graphicRef68895" href="/z/d/graphic/68895.html" rel="external">picture 5</a>); the average diameter is &gt;10 cm. Hypertrichosis is present in approximately one-half of cases [<a href="#rid22">22</a>], and there can be an associated smooth muscle hamartoma (sometimes evident clinically by perifollicular papules that are accentuated by rubbing). Associated developmental abnormalities, such as hypoplasia of the ipsilateral breast or pectoralis major muscle, occur infrequently.</p><p class="headingAnchor" id="H12"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>There are several considerations in the differential diagnosis of Becker nevi:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinically, a Becker nevus can be confused with a congenital melanocytic nevus; however, histologically, Becker nevi are not composed of melanocytic nevus cells. (See  <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">"Congenital melanocytic nevi"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Smooth muscle hamartomas have significant clinical and histologic overlap with Becker nevi.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plexiform neurofibromas, which often have hyperpigmentation and even hypertrichosis of the overlying skin, may be considered in the differential diagnosis of Becker nevi with an associated smooth muscle hamartoma. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Peripheral neurofibromas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depending on the location of the lesion and the number of peripheral islands, a Becker nevus without hypertrichosis can be difficult to distinguish from an isolated café-au-lait macule (CALM). (See <a class="local">'Café-au-lait macule'</a> above.)</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Management</span><span class="headingEndMark"> — </span>Patients with Becker nevi should be examined clinically for associated soft tissue and bony abnormalities. If desired for cosmetic reasons, the hyperpigmented component of Becker nevi can be treated with the quality-switched (Q-switched) ruby laser, the Q-switched neodymium:yttrium aluminum garnet (Nd:YAG) laser, or resurfacing lasers (although responses are variable and recurrence rates are high) and the associated hypertrichosis with laser-assisted hair removal. (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation", section on 'Becker's nevus'</a> and  <a class="medical medical_review" href="/z/d/html/1589.html" rel="external">"Removal of unwanted hair", section on 'Laser and intense pulsed light'</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">DERMAL MELANOCYTOSES</span><span class="headingEndMark"> — </span>In normal skin, only melanocytes in the epidermis and hair follicles produce melanin. In dermal melanocytoses, melanocytes in the dermis actively synthesize melanin. The blue color of such skin (ceruloderma) is due to the preferential scattering of shorter wavelengths of light by the dermal melanin, a phenomenon known as the Tyndall effect.</p><p>The spectrum of dermal melanocytoses includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Mongolian spots (sacral and extrasacral)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nevus of Ota-like macules/acquired dermal melanocytosis (grayish-brown macules in a bilateral, symmetric distribution on the malar cheeks and forehead, seen primarily in middle-aged Eastern Asian women)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nevus of Ota</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nevus of Ito</p><p></p><p>Nevus of Ito has some overlap with patch-type blue nevi, which represent dermal melanocytomas (ie, a proliferation of melanin-producing dermal melanocytes). (See  <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)", section on 'Blue nevi'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Congenital dermal melanocytosis (Mongolian spots)</span><span class="headingEndMark"> — </span>Congenital dermal melanocytosis (Mongolian spots) typically appears as congenital blue-gray patches with indefinite borders  (<a class="graphic graphic_picture graphicRef77805" href="/z/d/graphic/77805.html" rel="external">picture 6</a>), most often on the sacral area and buttocks in Asian and Black children. They are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/119230.html" rel="external">"Skin lesions in the newborn and infant", section on 'Dermal melanocytosis'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Nevus of Ota</span><span class="headingEndMark"> — </span>Nevus of Ota (oculodermal melanocytosis, nevus fuscocaeruleus ophthalmomaxillaris) is a type of dermal melanocytosis that preferentially involves the areas innervated by the first and second divisions of the trigeminal nerve [<a href="#rid23">23</a>]. These lesions differ from Mongolian spots clinically in their mottled, rather than uniform, pigmentation and histologically in their greater density of melanocytes within the upper reticular dermis.</p><p>Nevus of Ota occurs most commonly in Eastern Asian and Black individuals. The incidence in Japan, for example, is 1 to 2 per 1000. The female to male ratio is approximately 4:1. Up to 15 percent of lesions harbor somatic activating mutations in the <em>GNAQ </em>and <em>GNA11</em> genes encoding G protein alpha subunits [<a href="#rid24">24</a>].</p><p>The pigmentation is present at birth or within the first year of life in more than one-half of cases, and in the remainder, it becomes apparent around puberty; in both instances, the lesions persist. Patients present with speckled or mottled, grayish-brown to blue-black patches involving the skin, conjunctiva, sclera, tympanic membrane, or oral and nasal mucosa of the affected dermatomes  (<a class="graphic graphic_picture graphicRef77921" href="/z/d/graphic/77921.html" rel="external">picture 7</a>). Approximately 10 percent of patients have bilateral involvement. Superimposed elevated areas with the histologic features of blue nevi occasionally develop, and iris mammillations may be seen. (See  <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)", section on 'Blue nevi'</a>.)</p><p>Symptomatic or asymptomatic neurocutaneous melanosis can occur, typically with central nervous system (CNS) involvement ipsilateral to the skin lesions. Approximately 10 percent of patients develop glaucoma, and ipsilateral sensorineural hearing loss has also been described. (See  <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">"Congenital melanocytic nevi", section on 'Neurocutaneous melanosis'</a>.)</p><p>Melanoma may rarely develop in patients with nevus of Ota, with the uveal tract (ie, the choroid) being the most common primary site, followed by the CNS, orbit, and skin. Although the prevalence of nevus of Ota is higher in Asian patients, the majority of melanoma cases have occurred in White patients, with a mean age at diagnosis of approximately 50 years [<a href="#rid25">25</a>]. In a review of nearly 8000 patients with uveal melanoma, oculodermal melanocytosis was present in 3 percent of the cases [<a href="#rid26">26</a>]. Patients with uveal melanoma and oculodermal melanocytosis had a nearly two-fold increased risk of metastasis compared with those without dermal melanocytosis. (See  <a class="medical medical_review" href="/z/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Management</span><span class="headingEndMark"> — </span>Patients with nevus of Ota should be followed with annual ophthalmologic examinations and educated regarding the clinical signs of ocular and cutaneous melanoma (eg, pain or visual changes and a new papule or nodule, respectively). If patients are unable to perform cutaneous self-examinations, they should have longitudinal dermatologic evaluation. (See  <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents"</a>.)</p><p>The cutaneous discoloration of nevus of Ota can be treated with the quality-switched (Q-switched) ruby laser, Q-switched alexandrite laser, Q-switched neodymium:yttrium aluminum garnet (Nd:YAG) laser, or alexandrite picosecond laser. This typically requires several sessions, but the outcomes are usually good to excellent [<a href="#rid27">27</a>]. Hypo- or hyperpigmentation are potential side effects. (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation", section on 'Nevus of Ota'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Nevus of Ito</span><span class="headingEndMark"> — </span>Nevus of Ito (nevus fuscocaeruleus acromiodeltoideus) is a type of congenital dermal melanocytosis involving areas of skin innervated by the posterior supraclavicular and lateral brachiocutaneous nerves; it is otherwise clinically and histopathologically similar to nevus of Ota.</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lentigines</strong> – Lentigines are persistent, benign, pigmented macules (usually &lt;5 mm in diameter) that result from increased pigment production from epidermal melanocytes. Multiple lentigines may be seen in a variety of disorders  (<a class="graphic graphic_table graphicRef66428" href="/z/d/graphic/66428.html" rel="external">table 1</a>). Solar lentigines occur only in sun-exposed areas and represent a sign of photodamage that indicates an increased risk for the development of melanoma and nonmelanoma skin cancers during adulthood. (See <a class="local">'Lentigo'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Café-au-lait macules</strong> – Café-au-lait macules are flat, tan to dark brown pigmented lesions that may be present at birth or appear during early childhood  (<a class="graphic graphic_picture graphicRef57807" href="/z/d/graphic/57807.html" rel="external">picture 3A</a>). The presence of ≥6 café-au-lait macules is a criterion for the diagnosis of neurofibromatosis type 1 (NF1). (See <a class="local">'Café-au-lait macule'</a> above and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Becker nevus</strong> – Becker nevus is a benign cutaneous hamartoma with epidermal or dermal elements. Most Becker nevi are first noticed around puberty  (<a class="graphic graphic_picture graphicRef68895" href="/z/d/graphic/68895.html" rel="external">picture 5</a>), but some are apparent at birth. Considerations in the differential diagnosis of Becker nevus include café-au-lait macule, congenital melanocytic nevus, smooth muscle hamartoma, and plexiform neurofibroma. (See <a class="local">'Becker nevus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermal melanocytoses</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital dermal melanocytosis</strong> – Congenital dermal melanocytosis (Mongolian spots) typically appears as congenital, blue-gray, pigmented patches with poorly defined borders  (<a class="graphic graphic_picture graphicRef77805" href="/z/d/graphic/77805.html" rel="external">picture 6</a>). (See  <a class="medical medical_review" href="/z/d/html/119230.html" rel="external">"Skin lesions in the newborn and infant", section on 'Dermal melanocytosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nevus of Ota</strong> – Nevus of Ota primarily involves the areas of skin innervated by the first and second divisions of the trigeminal nerve  (<a class="graphic graphic_picture graphicRef77921" href="/z/d/graphic/77921.html" rel="external">picture 7</a>). Potential complications include symptomatic or asymptomatic neurocutaneous melanosis, glaucoma, sensorineural hearing loss, and melanoma. Patients with nevus of Ota should be followed with yearly ophthalmologic examinations and educated regarding the clinical signs of ocular and cutaneous melanoma. (See <a class="local">'Nevus of Ota'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nevus of Ito</strong> – Nevus of Ito resembles nevus of Ota clinically and histopathologically but involves the areas of skin innervated by the posterior supraclavicular and lateral brachiocutaneous nerves. (See <a class="local">'Nevus of Ito'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ber Rahman S, Bhawan J. Lentigo. Int J Dermatol 1996; 35:229.</a></li><li><a class="nounderline abstract_t">Gupta G, Williams RE, Mackie RM. The labial melanotic macule: a review of 79 cases. Br J Dermatol 1997; 136:772.</a></li><li><a class="nounderline abstract_t">Santana T, Queiroz A, Gonçales LMC, et al. Focal melanocytic lesions of the oral mucosa: An epidemiological and morphological study. Oral Dis 2023; 29:2723.</a></li><li><a class="nounderline abstract_t">HODGSON C. Senile lentigo. Arch Dermatol 1963; 87:197.</a></li><li><a class="nounderline abstract_t">De Giorgi V, Gori A, Salvati L, et al. Clinical and Dermoscopic Features of Vulvar Melanosis Over the Last 20 Years. JAMA Dermatol 2020; 156:1185.</a></li><li><a class="nounderline abstract_t">Ferrari A, Agozzino M, Ardigò M, et al. Dermoscopic and confocal microscopy patterns of vulvar mucosal melanotic macules. J Am Acad Dermatol 2014; 70:e81.</a></li><li><a class="nounderline abstract_t">Ferrari A, Buccini P, Covello R, et al. The ringlike pattern in vulvar melanosis: a new dermoscopic clue for diagnosis. Arch Dermatol 2008; 144:1030.</a></li><li><a class="nounderline abstract_t">Bastiaens M, ter Huurne J, Gruis N, et al. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet 2001; 10:1701.</a></li><li><a class="nounderline abstract_t">Landau M, Krafchik BR. The diagnostic value of café-au-lait macules. J Am Acad Dermatol 1999; 40:877.</a></li><li><a class="nounderline abstract_t">Boyd KP, Gao L, Feng R, et al. Phenotypic variability among café-au-lait macules in neurofibromatosis type 1. J Am Acad Dermatol 2010; 63:440.</a></li><li><a class="nounderline abstract_t">Ahn JS, Kim SD, Hwang JH, et al. Halo-like disappearance of mongolian spot combined with café au lait spot. Pediatr Dermatol 1998; 15:70.</a></li><li><a class="nounderline abstract_t">Korf BR. Diagnostic outcome in children with multiple café au lait spots. Pediatrics 1992; 90:924.</a></li><li><a class="nounderline abstract_t">Nunley KS, Gao F, Albers AC, et al. Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol 2009; 145:883.</a></li><li><a class="nounderline abstract_t">Pasmant E, Sabbagh A, Hanna N, et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet 2009; 46:425.</a></li><li><a class="nounderline abstract_t">Arnsmeier SL, Riccardi VM, Paller AS. Familial multiple cafe au lait spots. Arch Dermatol 1994; 130:1425.</a></li><li><a class="nounderline abstract_t">Charrow J, Listernick R, Ward K. Autosomal dominant multiple café-au-lait spots and neurofibromatosis-1: evidence of non-linkage. Am J Med Genet 1993; 45:606.</a></li><li><a class="nounderline abstract_t">Abeliovich D, Gelman-Kohan Z, Silverstein S, et al. Familial café au lait spots: a variant of neurofibromatosis type 1. J Med Genet 1995; 32:985.</a></li><li><a class="nounderline abstract_t">Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics 2009; 123:124.</a></li><li><a class="nounderline abstract_t">Miller DT, Freedenberg D, Schorry E, et al. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Person JR, Longcope C. Becker's nevus: an androgen-mediated hyperplasia with increased androgen receptors. J Am Acad Dermatol 1984; 10:235.</a></li><li><a class="nounderline abstract_t">Cai ED, Sun BK, Chiang A, et al. Postzygotic Mutations in Beta-Actin Are Associated with Becker's Nevus and Becker's Nevus Syndrome. J Invest Dermatol 2017; 137:1795.</a></li><li><a class="nounderline abstract_t">Tymen R, Forestier JF, Boutet B, Colomb D. [Late Becker's nevus. One hundred cases (author's transl)]. Ann Dermatol Venereol 1981; 108:41.</a></li><li><a class="nounderline abstract_t">Hori Y, Takayama O. Circumscribed dermal melanoses. Classification and histologic features. Dermatol Clin 1988; 6:315.</a></li><li><a class="nounderline abstract_t">Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191.</a></li><li><a class="nounderline abstract_t">Shaffer D, Walker K, Weiss GR. Malignant melanoma in a Hispanic male with nevus of Ota. Dermatology 1992; 185:146.</a></li><li><a class="nounderline abstract_t">Shields CL, Kaliki S, Livesey M, et al. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol 2013; 131:993.</a></li><li><a class="nounderline abstract_t">Watanabe S, Takahashi H. Treatment of nevus of Ota with the Q-switched ruby laser. N Engl J Med 1994; 331:1745.</a></li></ol></div><div id="topicVersionRevision">Topic 5560 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8786179" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lentigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205516" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The labial melanotic macule: a review of 79 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36565435" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Focal melanocytic lesions of the oral mucosa: An epidemiological and morphological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13963796" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Senile lentigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785609" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical and Dermoscopic Features of Vulvar Melanosis Over the Last 20 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24629367" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dermoscopic and confocal microscopy patterns of vulvar mucosal melanotic macules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711077" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The ringlike pattern in vulvar melanosis: a new dermoscopic clue for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487574" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The melanocortin-1-receptor gene is the major freckle gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10365918" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The diagnostic value of café-au-lait macules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20605257" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Phenotypic variability among café-au-lait macules in neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9496813" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Halo-like disappearance of mongolian spot combined with caféau lait spot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1344978" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diagnostic outcome in children with multiple caféau lait spots.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687418" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Predictive value of caféau lait macules at initial consultation in the diagnosis of neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19366998" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979446" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Familial multiple cafe au lait spots.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8456833" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Autosomal dominant multiple café-au-lait spots and neurofibromatosis-1: evidence of non-linkage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8825931" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Familial caféau lait spots: a variant of neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117870" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Neurofibromatosis type 1 revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010905" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Health Supervision for Children With Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6715592" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Becker's nevus: an androgen-mediated hyperplasia with increased androgen receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28347698" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Postzygotic Mutations in Beta-Actin Are Associated with Becker's Nevus and Becker's Nevus Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7235503" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : [Late Becker's nevus. One hundred cases (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3378374" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Circumscribed dermal melanoses. Classification and histologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083380" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mutations in GNA11 in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1421629" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Malignant melanoma in a Hispanic male with nevus of Ota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23681424" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7984195" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of nevus of Ota with the Q-switched ruby laser.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
